Andrew T Bayman

Andy Bayman is a trial lawyer who represents pharmaceutical companies, medical device manufacturers, retailers, automotive manufacturers and other major companies in complex and novel product liability, toxic tort, and other tort cases.

Andy has tried over 20 cases in state and federal courts, many of which are first of kind such as the first pharmaceutical products liability lawsuit ever tried under the theory of “Innovator Liability,” the first MDL bellwether trial involving an atypical femur fracture allegedly caused by Merck’s osteoporosis medicine, Fosamax® and, more recently, the first Zantac case to go to trial.

Mr. Bayman is often called upon as coordinating and lead counsel on some of the most brand-threatening, high-profile crisis matters for major manufacturers, many of which are in MDLs. He is lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and one of four Defense Co-Leads in personal injury and class actions in the In Re Zantac MDL in the United States District Court for the Southern District of Florida and in coordinated state court proceedings in various states.